Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HBM7008 |
Synonyms | |
Therapy Description |
HBM7008 is a bispecific antibody targeting VTCN1 (B7-H4) and TNFRSF9 (4-1BB), which potentially results in activation of T-lymphocytes and antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HBM7008 | HBM 7008|HBM-7008 | TNFRSF9 Antibody 32 | HBM7008 is a bispecific antibody targeting VTCN1 (B7-H4) and TNFRSF9 (4-1BB), which potentially results in activation of T-lymphocytes and antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |